M.D. Anderson Cancer Center: Primary Myelofibrosis trials

The registry lists 28 Primary Myelofibrosis studies with M.D. Anderson Cancer Center as lead sponsor. 3 are open to participants now and 16 have results posted.

Early Phase 1 1Phase 1 6Phase 2 26Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)RecruitingNCT07128381Phase 1/2
• High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyRecruitingNCT06345495Phase 2
• Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)RecruitingNCT06327100Phase 1/2
• Long-Term Side Effects of Ruxolitinib in Treating Patients With MyelofibrosisCompletedNCT02784496Phase 2Results posted
• Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and AnemiaTerminatedNCT02730884Phase 2Results posted
• Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera MyelofibrosisTerminatedNCT02421354Phase 2Results posted
• Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)CompletedNCT02267278Phase 2Results posted
• LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisCompletedNCT02098161Phase 2Results posted
• Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaCompletedNCT01712308Phase 2Results posted
• Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase TherapyCompletedNCT01428635Phase 2/3Results posted
• Ruxolitinib and Lenalidomide for Patients With MyelofibrosisCompletedNCT01375140Phase 2Results posted
• Study of SB939 in Subjects With MyelofibrosisCompletedNCT01200498Phase 2Results posted
• Pomalidomide for Myelofibrosis PatientsCompletedNCT00946270Phase 2Results posted
• Ph II Study of Azacitidine in MyelofibrosisCompletedNCT00569660Phase 2Results posted
• CEP-701 for PH-negative MyelofibrosisCompletedNCT00494585Phase 2Results posted
• Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic SyndromeCompletedNCT00475020Phase 2Results posted
• Lenalidomide for Patients With Myelofibrosis (MF)CompletedNCT00352794Phase 2Results posted
• Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)CompletedNCT00255346Phase 2Results posted
• A Phase II Study of CC-5013 in MyelofibrosisCompletedNCT00087672Phase 2Results posted
• A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With MyelofibrosisWithdrawnNCT06619522Phase 2
• Elotuzumab for the Treatment of JAK2-Mutated MyelofibrosisActive, not recruitingNCT04517851Phase 2
• PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisWithdrawnNCT04054245Phase 2
• Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/2
• Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisCompletedNCT03426969Early Phase 1
• Hu8F4 in Treating Patients With Advanced Hematologic MalignanciesActive, not recruitingNCT02530034Phase 1
• Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative NeoplasmCompletedNCT01787487Phase 2
• PTK 787 and Gleevec in Patients With AML, AMM, and CML-BPCompletedNCT00088231Phase 1/2
• RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell LymphomaCompletedNCT00081874Phase 1/2